Drug intelligence / Profile preview

V932

Development stage: Phase 1
Lead developer: Merck
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

V932 is a biological vaccine candidate developed by Merck Sharp & Dohme LLC. It is currently undergoing a Phase I clinical trial to evaluate its safety, tolerability, and immunogenicity in cancer patients whose tumors express Human epidermal growth factor receptor 2 (HER-2) and/or Carcinoembryonic antigen (CEA). The vaccine is administered via intramuscular injection.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on V932.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on V932.

Explore the full profile